Use of genomics and combinatorial chemistry in the development of new antimycobacterial drugs

Biochemical Pharmacology

Volumn 59, Issue 3, 2000, Pages 221-231

  Barry, Clifton E ^a   Slayden, Richard A ^a   Sampson, Andrea E ^a   Lee, Richard E ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Drug design; Genomics; Isoniazid; Microarray; Mycobacteria; Mycobacterium tuberculosis; Tuberculosis

Indexed keywords

ANTIMYCOBACTERIAL AGENT; CATALASE; ISONIAZID; PEROXIDASE;

BACTERIUM ISOLATE; CELL ACTIVATION; DRUG DESIGN; DRUG MECHANISM; GENE EXPRESSION; GENOME; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; TUBERCULOSIS;

ANIMALS; ANTITUBERCULAR AGENTS; BIOTRANSFORMATION; COMBINATORIAL CHEMISTRY TECHNIQUES; DRUG DESIGN; DRUG RESISTANCE, MICROBIAL; GENOME, BACTERIAL; HUMANS; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; PRODRUGS; STRUCTURE-ACTIVITY RELATIONSHIP; TUBERCULOSIS;

EID: 0033986977     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(99)00253-1     Document Type: Article

References (84)

1. Farmer P., Bayona J., Becerra M., Furin J., Henry C., Hiatt H., Kim J.Y., Mitnick C., Nardell E., Shin S. The dilemma of MDR-TB in the global era. Int J Tuberc Lung Dis. 2:1998;869-876.
2. Viskum K., Kok-Jensen A. Multidrug-resistant tuberculosis in Denmark, 1993-1995. Int J Tuberc Lung Dis. 1:1997;299-301.
3. Kruuner A., Sillastu H., Danilovitsh M., Levina K., Svenson S.B., Kallenius G., Hoffner S.E. Drug resistant tuberculosis in Estonia. Int J Tuberc Lung Dis. 2:1998;130-133.
4. Pablos-Mendez A., Raviglione M.C., Laszlo A., Binkin N., Rieder H.L., Bustreo F., Cohn D.L., Lambregts-van Weezenbeek C.S., Kim S.J., Chaulet P., Nunn P. Global surveillance for antituberculosis-drug resistance, 1994-1997. World Health Organization-International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance. [published erratum appears in N Engl J Med 339: 139, 1998]. N Engl J Med. 338:1998;1641-1649.
5. Bass J.B. Jr, Farer L.S., Hopewell P.C., O'Brien R., Jacobs R.F., Ruben F., Snider D.E. Jr, Thornton G. Treatment of tuberculosis and tuberculosis infection in adults and children. Am J Respir Crit Care Med. 149:1994;1359-1374.
6. Dollery SC, Therapeutic Drugs, Vol. 2. Churchill Livingstone, London, 1991.
7. Snyder I., Finch R. Drugs used in the treatment of tuberculosis and leprosy. Craig C., Stitzel R. Modern Pharmacology. 1997;707-719 Little, Brown & Co, Boston.
8. Knoben J and Anderson P, Handbook of Clinical Drug Data. Drug Intelligence Publications, Hamilton, IL, 1993.
9. Mitchison D.A. How drug resistance emerges as a result of poor compliance during short course chemotherapy for tuberculosis. Int J Tuberc Lung Dis. 2:1998;10-15.
10. Cole S.T., Brosch R., Parkhill J., Garnier T., Churcher C., Harris D., Gordon S.V., Eiglmeier K., Gas S., Barry C.E. III, Tekaia F., Badcock K., Basham D., Brown D., Chillingworth T., Connor R., Davies R., Devlin K., Feltwell T., Gentles S., Hamlin N., Holroyd S., Hornsby T., Jagels K., Krogh A., McLean J., Moule S., Murphy L., Oliver K., Osborne J., Quail M.A., Rajandream M.-A., Rogers J., Rutter S., Seeger K., Skelton J., Squares R., Squares S., Sulston J.E., Taylor K., Whitehead S., Barrell B.G. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. [published erratum appears in Nature 396: 190, 1998]. Nature. 393:1998;537-544.
11. Barry C.E. III. New horizons in the treatment of tuberculosis. Biochem Pharmacol. 54:1997;1165-1172.
12. Debouck C., Goodfellow P.N. DNA microarrays in drug discovery and development. Nat Genet. 21:(Suppl 1):1999;48-50.
13. Schena M., Heller R.A., Theriault T.P., Konrad K., Lachenmeier E., Davis R.W. Microarrays Biotechnology's discovery platform for functional genomics. Trends Biotechnol. 16:1998;301-306.
14. Schena M. Genome analysis with gene expression microarrays. Bioessays. 18:1996;427-431.
15. Marton M.J., DeRisi J.L., Bennett H.A., Iyer V.R., Meyer M.R., Roberts C.J., Stoughton R., Burchard J., Slade D., Dai H., Bassett D.E. Jr, Hartwell L.H., Brown P.O., Friend S.H. Drug target validation and identification of secondary drug target effects using DNA microarrays. Nat Med. 4:1998;1293-1301.
16. Gingeras T.R., Ghandour G., Wang E., Berno A., Small P.M., Drobniewski F., Alland D., Desmond E., Holodniy M., Drenkow J. Simultaneous genotyping and species identification using hybridization pattern recognition analysis of generic Mycobacterium DNA arrays. Genome Res. 8:1998;435-448.
17. Mullner S., Neumann T., Lottspeich F. Proteomics - a new way for drug target discovery. Arzneimittelforschung. 48:1998;93-95.
18. Urquhart B.L., Atsalos T.E., Roach D., Basseal D.J., Bjellqvist B., Britton W.L., Humphery-Smith I. 'Proteomic contigs' of Mycobacterium tuberculosis and Mycobacterium bovis (BCG) using novel immobilised pH gradients. Electrophoresis. 18:1997;1384-1392.
19. Mdluli K., Slayden R.A., Zhu Y., Ramaswamy S., Pan X., Mead D., Crane D.D., Musser J.M., Barry C.E. III. Inhibition of a Mycobacterium tuberculosis β-ketoacyl ACP synthase by isoniazid. Science. 280:1998;1607-1610.
20. Bailey D.S., Bondar A., Furness L.M. Pharmacogenomics - it's not just pharmacogenetics. Curr Opin Biotechnol. 9:1998;595-601.
21. Veber D.F., Drake F.H., Gowen M. The new partnership of genomics and chemistry for accelerated drug development. Curr Opin Chem Biol. 1:1997;151-156.
22. Ajay A., Walters W.P., Murcko M.A. Can we learn to distinguish between "drug-like" and "nondrug-like" molecules? J Med Chem. 41:1998;3314-3324.
23. Sadowski J., Kubinyi H. A scoring scheme for discriminating between drugs and nondrugs. J Med Chem. 41:1998;3325-3329.
24. Lipinski C.A., Lombardo F., Dominy B.W., Feeney P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Delivery Rev. 23:1997;3-25.
25. Ghose A.K., Viswandhan V.N., Wendoloski J.J. A knowledge-based approach in designing combinatorial or medicinal chemistry libraries for drug discovery. 1. A qualitative and quantitative characterization of known drug databases. J Comb Chem. 1:1999;55-68.
26. Bergmann K.E., Cynamon M.H., Welch J.T. Quantitative structure-activity relationships for the in vitro antimycobacterial activity of pyrazinoic acid esters. J Med Chem. 39:1996;3394-3400.
27. Renau T.E., Sanchez J.P., Shapiro M.A., Dever J.A., Gracheck S.J., Domagala J.M. Effect of lipophilicity at N-1 on activity of fluoroquinolones against mycobacteria. J Med Chem. 38:1995;2974-2977.
28. Renau T.E., Sanchez J.P., Gage J.W., Dever J.A., Shapiro M.A., Gracheck S.J., Domagala J.M. Structure-activity relationships of the quinolone antibacterials against mycobacteria Effect of structural changes at N-1 and C-7. J Med Chem. 39:1996;729-735.
29. Renau T.E., Gage J.W., Dever J.A., Roland G.E., Joannides E.T., Shapiro M.A., Sanchez J.P., Gracheck S.J., Domagala J.M., Jacobs M.R., Reynolds R.C. Structure-activity relationships of quinolone agents against mycobacteria Effect of structural modifications at the 8 position. Antimicrob Agents Chemother. 40:1996;2363-2368.
30. Morrison N.E., Collins F.M. Antimycobacterial activity of 2-acetylpyridine thiosemicarbazones in relation to their antileprosy activity. Int J Lepr. 49:1981;180-186.
31. Waisser K., Kunes J., Klimes J., Polasek M., Odlerova Z. Relations between structure and antituberculotic activity of 4-alkoxybenzoic acids. Collect Czech Chem Commun. 58:1993;191-196.
32. Josefson D. FDA approves tuberculosis drug. BMJ. 317:1998;11.
33. Jarvis B and Lamb HM, Rifapentine. Drugs 56: 607-616; discussion 617, 1998.
34. Hidaka T. Current status and perspectives on the development of rifamycin derivative antibiotics. Kekkaku. 74:1999;53-61.
35. Middlebrook G. Sterilization of tubercle bacilli by isonicotinic acid hydrazide and the incidence of variants resistant to the drug in vitro. Am Rev Tuberc. 65:1952;765-767.
36. Middlebrook G. Isoniazid-resistance and catalase activity of tubercle bacilli. Am Rev Tuberc. 69:1954;471-472.
37. Dobner P., Rusch-Gerdes S., Bretzel G., Feldmann K., Rifai M., Loscher T., Rinder H. Usefulness of Mycobacterium tuberculosis genomic mutations in the genes katG and inhA for the prediction of isoniazid resistance. Int J Tuberc Lung Dis. 1:1997;365-369.
38. Musser J.M., Kapur V., Williams D.L., Kreiswirth B.N., van Soolingen D., van Embden J.D.A. Characterization of the catalase-peroxidase gene (katG) and inhA locus in isoniazid-resistant and -susceptible strains of Mycobacterium tuberculosis by automated DNA sequencing Restricted array of mutations associated with drug resistance. J Infect Dis. 173:1996;196-202.
39. Musser J.M. Antimicrobial agent resistance in mycobacteria Molecular genetic insights. Clin Microbiol Rev. 8:1995;496-514.
40. Marttila H.J., Soini H., Huovinen P., Viljanen M.K. katG mutations in isoniazid-resistant Mycobacterium tuberculosis isolates recovered from Finnish patients. Antimicrob Agents Chemother. 40:1996;2187-2189.
41. Marttila H.J., Soini H., Eerola E., Vyshnevskaya E., Vyshnevskiy B.I., Otten T.F., Vasilyef A.V., Viljanen M.K. A Ser315Thr substitution in KatG is predominant in genetically heterogeneous multidrug-resistant Mycobacterium tuberculosis isolates originating from the St. Petersburg area in Russia. Antimicrob Agents Chemother. 42:1998;2443-2445.
42. Banerjee A., Dubnau E., Quemard A., Balasubramanian V., Um K.S., Wilson T., Collins D., de Lisle G., Jacobs W.R. Jr. inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis. Science. 263:1994;227-230.
43. Winder F.G., Collins P.B., Whelan D. Effects of ethionamide and isoxyl on mycolic acid synthesis in Mycobacterium tuberculosis BCG. J Gen Microbiol. 66:1971;379-380.
44. Quemard A., Laneelle G., Lacave C. Mycolic acid synthesis A target for ethionamide in mycobacteria? Antimicrob Agents Chemother. 36:1992;1316-1321.
45. Johnsson K., King D.S., Schultz P.G. Studies on the mechanism of action of isoniazid and ethionamide in the chemotherapy of tuberculosis. J Am Chem Soc. 117:1995;5009-5010.
46. Prema K., Gopinthan K.P. Distribution, induction and purification of a monooxygenase catalyzing sulfoxidation of drugs. Biochem Pharmacol. 25:1976;1299-1303.
47. Bieder A., Brunel P., Roquet-Ghaye J., Kries B. Evolution des concentrations seriques en ethionamide et en sulfoxide d'ethionamide apres administration orale de ces deux tuberculostatiques chez l'homme. Rev Fr Etud Clin Biol. 11:1966;419-423.
48. Grunert M., Iwainsky H. On the metabolism of ethionamide and its sulfoxide in the macroorganism. Arzneimittelforschung. 17:1967;411-415.
49. Cashman J.R., Hanzlik R.P. Oxidation and other reactions of thiobenzamide derivatives of relevance to their hepatotoxicity. J Org Chem. 47:1982;4645-4650.
50. Porter W.R., Gudzinowicz M.J., Neal R.A. Thioacetamide-induced hepatic necrosis. II. Pharmacokinetics of thioacetamide and thioacetamide-S-oxide in the rat. J Pharmacol Exp Ther. 208:1979;386-391.
51. Porter W.R., Neal R.A. Metabolism of thioacetamide and thioacetamide S-oxide by rat liver microsomes. Drug Metab Dispos. 6:1978;379-388.
52. Konopka E.A., Gisi T., Eisman P.C., Mayer R.L. Antituberculosis activity of substituted thioureas. IV. Studies with 4-butoxy-4-dimethylaminothiocarbanilide (Su 1906). Proc Soc Exp Biol Med. 89:1955;388-398.
53. Bartmann K. Kreuzresistenz zwischen α-äthyl-thioisonicotinamid (1314 Th) und thiosemikarbazon (Conteben). Tuberk-Arzt. 14:1960;525-532.
54. Tskamura M. In vivo relationship between α-ethyl-thioisonicotinamide resistance and thiosemicarbazone resistance of tubercle bacilli in patients. Kekkaku. 37:1962;103-113.
55. Eule H., Bethge W., Werner E. Klinische beobuchtungen mit dem neunen tuberkulostatikum aethionamide. Z Tuberk. 118:1962;170-180.
56. Urbancik R., Trnka L. Report on the antimicrobial activity of Isoxyl on Mycobacterium tuberculosis. Acta Tuberc Pneumol Belg. 54:1963;66-86.
57. Verbist L. Susceptibility of mycobacteria to 4,4′-diisoamyl-oxythiocarbanilide. Antimicrob Agents Chemother. 5:1965;298-305.
58. Sojkova M., Tousek J., Trnka L. Cross resistance of human tubercle bacilli to ethionamide, thiosemicarbazone and substituted thioureas. Prax Pneumol. 19:1965;522-527.
59. Tan T.H., The K.S., Yang S.Y., Tan L.S., Ko H.L., Tjie H.B., Chatim A. Studies on cross-resistance between isoniazid, isoxyl, teebazone, ethionamide and ethambutol of tubercle bacilli from patients never treated with those drugs except with isoniazid. Paediatr Indones. 6:1966;32-38.
60. Afanas'eva IuP, Mkrtchian S.V. Criteria of M. tuberculosis resistance to thioacetazone and of cross resistance to ethionamide. Probl Tuberk. 47:1969;66-69.
61. Muzikravic T. Chemoresistance to Isoxyl. Its determination and its evaluation. Antibiot Chemother. 16:1970;177-181.
62. Osato T., Tsukagoshi K., Shimizu H. Studies on the thiacetazone resistance of tubercle bacilli. Kekkaku. 46:1971;89-92.
63. Yeager R.L., Munroe W.G., Dessar F.I. Pyrazinamide (Aldinamide) in the treatment of pulmonary tuberculosis. Am Rev Tuberc. 65:1952;523-534.
64. Snider D.E. Jr, Rogowski J., Zierski M., Bek E., Long M.W. Successful intermittent treatment of smear-positive pulmonary tuberculosis in six months A cooperative study in Poland. Am Rev Respir Dis. 125:1982;265-267.
65. Heifets L., Lindholm-Levy P. Pyrazinamide sterilizing activity in vitro against semidormant Mycobacterium tuberculosis bacterial populations. Am Rev Respir Dis. 145:1992;1223-1225.
66. Scorpio A., Zhang Y. Mutations in pncA, a gene encoding pyrazinamidase/nicotinamidase, cause resistance to the antituberculous drug pyrazinamide in tubercle bacillus. Nat Med. 2:1996;662-667.
67. Hirano K., Takahashi M., Kazumi Y., Fukasawa Y., Abe C. Mutation in pncA is a major mechanism of pyrazinamide resistance in Mycobacterium tuberculosis. Tuber Lung Dis. 78:1997;117-122.
68. Scorpio A., Lindholm-Levy P., Heifets L., Gilman R., Siddiqi S., Cynamon M., Zhang Y. Characterization of pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis. Antimicrob Agents Chemother. 41:1997;540-543.
69. Konno K., Feldmann F.M., McDermott W. Pyrazinamide susceptibility and amidase activity of tubercle bacilli. Am Rev Respir Dis. 95:1967;461-469.
70. Zhang Y., Scorpio A., Nikaido H., Sun Z. Role of acid pH and deficient efflux of pyrazinoic acid in unique susceptibility of Mycobacterium tuberculosis to pyrazinamide. J Bacteriol. 181:1999;2044-2049.
71. Wächter G.A., Davis M.C., Martin A.R., Franzblau S.G. Antimycobacterial activity of substituted isosteres of pyridine- and pyrazinecarboxylic acids. J Med Chem. 41:1998;2436-2438.
72. Yamamoto S., Toida I., Watanabe N., Ura T. In vitro antimycobacterial activities of pyrazinamide analogs Results of screening tests. Kekkaku. 71:1996;253-258.
73. Speirs R.J., Welch J.T., Cynamon M.H. Activity of n-propyl pyrazinoate against pyrazinamide-resistant Mycobacterium tuberculosis Investigations into mechanism of action of and mechanism of resistance to pyrazinamide. Antimicrob Agents Chemother. 39:1995;1269-1271.
74. Wayne L.G., Sramek H.A. Metronidazole is bactericidal to dormant cells of Mycobacterium tuberculosis. Antimicrob Agents Chemother. 38:1994;2054-2058.
75. Dhillon J., Allen B.W., Hu Y.M., Coates A.R., Mitchison D.A. Metronidazole has no antibacterial effect in Cornell model murine tuberculosis. Int J Tuberc Lung Dis. 2:1998;736-742.
76. Paramasivan C.N., Kubendiran G., Herbert D. Action of metronidazole in combination with isoniazid and rifampicin on persisting organisms in experimental murine tuberculosis. Indian J Med Res. 108:1998;115-119.
77. Ashtekar D.R., Costa-Perira R., Nagrajan K., Vishvanathan N., Bhatt A.D., Rittel W. In vitro and in vivo activities of the nitroimidazole CGI 17341 against Mycobacterium tuberculosis. Antimicrob Agents Chemother. 37:1993;183-186.
78. Townson S.M., Boreham P.F., Upcroft P., Upcroft J.A. Resistance to the nitroheterocyclic drugs. Acta Trop. 56:1994;173-194.
79. Tocher J.H. Reductive activation of nitroheterocyclic compounds. Gen Pharmacol. 28:1997;485-487.
80. Sherman D.R., Sabo P.J., Hickey M.J., Arain T.M., Mahairas G.G., Yuan Y., Barry C.E. III, Stover C.K. Disparate responses to oxidative stress in saprophytic and pathogenic mycobacteria. Proc Natl Acad Sci USA. 92:1995;6625-6629.
81. Mdluli K., Swanson J., Fischer E., Lee R.E., Barry C.E. III. Mechanisms involved in the intrinsic isoniazid resistance of Mycobacterium avium. Mol Microbiol. 27:1998;1223-1233.
82. Cole S.T. Rifamycin resistance in mycobacteria. Res Microbiol. 147:1996;48-52.
83. Musser J.M. Antimicrobial agent resistance in mycobacteria Molecular genetic insights. Clin Microbiol Rev. 8:1995;496-514.
84. Sherman D.R., Mdluli K., Hickey M.J., Arain T.M., Morris S.L., Barry C.E. III, Stover C.K. Compensatory ahpC gene expression in isoniazid-resistant Mycobacterium tuberculosis. Science. 272:1996;1641-1643.